Stroke clinical trials at UC Davis
2 research studies open to eligible people
“This study hopes to learn whether there are changes in the genetic material of people who have had a stroke or brain hemorrhage”
open to eligible people ages 18 years and up
This study will evaluate whether a gene marker can improve the identification of atrial fibrillation in patients with ischemic stroke, and evaluate whether the decision to anticoagulate could be improved by a marker of atrial fibrillation.
Effectiveness and Safety of Experimental BIIB093 (Glibenclamide) for Severe Cerebral Edema (fluid around brain) After Stroke
open to eligible people ages 18-85
The primary objective is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric Infarction (LHI). The secondary objectives are to determine if BIIB093 improves overall survival at Day 90 when compared with placebo, if BIIB093 improves functional outcome at Day 90 on the mRS dichotomized 0-4 vs. 5-6 when compared with placebo, if BIIB093 reduces midline shift at 72 hours (or at time of decompressive craniectomy [DC] or comfort measures only [CMO], if earlier) when compared with placebo, and to evaluate the safety and tolerability of BIIB093 in participants with LHI.
Sacramento, California and other locations